Scilex Presents Results of Semdexa (SP-102) in P-III (SEMDEXA) Trial for the Treatment of Sciatica Pain Management at ASIPP 2022
- The P-III (C.L.E.A.R.) trial evaluates semdexa vs PBO in 401 patients with lumbosacral radicular pain or sciatica
- The trial met its 1EPs i.e., reduction in avg. daily leg pain for ~99 days following single inj. & the median time to repeat inj. @Days 57 & 99, safety profile with no safety risks, no serious AEs patients were eligible to receive an additional SP-102 inj after experienced radicular pain reduction b/w 4 & 23wks.
- The 2EPs of ODI & other measured showed 28% improvement @4wks. on SP-102 over baseline. Under the SPAC with Vickers, the combined company will be renamed Scilex & its common stock will be listed on Nasdaq with ticker symbol “SCLX”
Ref: Globenewswire | Image: Scilex
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.